Company News in the Life Science Industry

»

Reset 

Oncology Venture has established bridge loan facility

Read more ››
By: Nasdaq / GlobenewsWire - 22 Mar 2019

Herantis Pharma Plc: Change in the number of shares and voting rights

Read more ››
By: Nasdaq / GlobenewsWire - 22 Mar 2019

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Read more ››
By: Nasdaq / GlobenewsWire - 22 Mar 2019
Related companies:  Genmab A/S

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Read more ››
By: Nasdaq / GlobenewsWire - 22 Mar 2019
Related companies:  Sorrento Therapeutics, Inc.

Bruker Announces Improved Assay for Tuberculosis Diagnostics in Novel Liquid Array(TM) Format for Improved Multiplexing

NEHREN, Germany, March 22, 2019 /PRNewswire/ -- In time for the World Tuberculosis (TB) Day 2019 on Sunday, March 24(th) (Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019

Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

STOCKHOLM, March 22, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in Europe. Two Phase 3-studies are currently underway in North America and Europe with topline results... Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019
Related companies:  Moberg Pharma AB (Publ)

Evox Therapeutics Awarded £1.5 Million in Funding From Innovate UK

OXFORD, England, March 22, 2019 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, today announces that it has secured £1.5 million in funding from Innovate UK, the UK's Innovation Agency, through the Biomedical Catalyst Early Stage Award.... Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019

Alligator Bioscience's Annual Report 2018 Published

LUND, Sweden, March 22, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the Annual Report 2018 is available at the company website Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019

Exscientia Continues Expansion with Establishment of a Subsidiary in Japan to Target the Pharmaceutical Market Across Asia

OXFORD, England and OSAKA, Japan, March 22, 2019 /PRNewswire/ -- Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company announces the establishment of a subsidiary, Exscientia K.K to spearhead its pharmaceutical interests across Asia.

Read more ››
By: PR Newswire Association LLC. - 22 Mar 2019

Redsense Receives Patent Approval in Sweden for its Smart Wound Care Technology for Optical Measuring of Blood and Exudate

STOCKHOLM, March 22, 2019 /PRNewswire/ -- Redsense Medical announces that the company will receive a patent approval in Sweden for the innovative smart wound care technology that was presented in November, 2018. The patent covers optical sensor measuring and will be valid until 2038.

... Read more ››
By: PR Newswire Association LLC. - 22 Mar 2019

Sciton Announces Excellent Outcomes from Deep Perioral Er:Yag Laser Resurfacing in Multiyear Retrospective Study

PALO ALTO, Calif., March 22, 2019 /PRNewswire/ -- Sciton®, a leading manufacturer of high-quality laser and light systems in the aesthetic and medical market, is announcing the long-term results of perioral rhytid correction with its Contour TRL Er:Yag laser.

Read more ››
By: PR Newswire Association LLC. - 22 Mar 2019
Related companies:  Sciton, Inc.

Global $4.7 Bn Alcohol Testing and Drug Testing Market, 2019-2025 - Markets are Poised to Achieve Significant Growth as Law Enforcement and Companies Test for Substance Abuse

DUBLIN, March 22, 2019 /PRNewswire/ -- The "Alcohol Testing and Drug Testing: Market Shares, Strategies, and Forecasts, Worldwide, 2019-2025" report from Wintergreen Research, Inc has been added... Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019

Bone Densitometers Market to Reach US$ 1.11 Bn by 2024, Rising Cases of Osteoporosis to Drive Demand - TMR

ALBANY, New York, March 22, 2019 /PRNewswire/ -- The global bone densitometers market has opened doors for entry for small players, thanks to the its innovative and fragmented landscape, reports... Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019
Related companies:  Transparency Market Research

Global Irritable Bowel Syndrome Partnering Deals and Agreements 2014-2019 by Company A-Z, Deal Value, Industry Sector, Deal Type, Stage Of Development, & Technology Area

DUBLIN, March 22, 2019 /PRNewswire/ -- The "Global Irritable Bowel Syndrome Partnering 2014-2019" report has been added to ResearchAndMarkets.com's offering.

Read more ››
By: PR Newswire Association LLC. - 22 Mar 2019

Invisible Ink Tattoo Removers Unveils New Ambassador Program With $100 Rewards to Promote Regret-Free Tattoo Changes

CINCINNATI, March 22, 2019 /PRNewswire/ -- Invisible Ink Tattoo Removers, America's leading specialty provider of tattoo removal, fading and change services with more than 60,000 successful treatments, announced today the launch of the company's Ambassador program. The new referral and reward... Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019

UCB SA/NV: Convening Notice to attend the general meeting of shareholders to be held at Bluepoint Brussels

Read more ››
By: Nasdaq / GlobenewsWire - 22 Mar 2019

Novartis plans for Alcon spin-off on April 9, 2019

Read more ››
By: Nasdaq / GlobenewsWire - 22 Mar 2019
Related companies:  Novan, Inc.

Sosei Heptares Announces that Ultibro® Breezhaler® and Seebri® Breezhaler® Launched in China for the Treatment of COPD

TOKYO and LONDON, March 21, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro® Breezhaler® and Seebri® Breezhaler® have been launched by Novartis in China for the treatment of chronic obstructive pulmonary disease (COPD). The Company, together with... Read more ››

By: PR Newswire Association LLC. - 22 Mar 2019

BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease

STOCKHOLM, Sweden, March 21, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401 in patients with early Alzheimer´s disease.

Read more ››
By: PR Newswire Association LLC. - 22 Mar 2019

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer’s Disease

Read more ››
By: Nasdaq / GlobenewsWire - 21 Mar 2019
Related companies:  ProMIS Neurosciences, Inc.
«  1  2  3  4 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Explore our database of over 50,000 companies